Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06149247 · ClinicalTrials.gov registry record · Phase 2
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
A Phase 2 study of Cutaneous T-Cell Lymphoma/Mycosis Fungoides, sponsored by Soligenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06149247 is a Phase 2 study of Cutaneous T-Cell Lymphoma/Mycosis Fungoides that has completed, run by Soligenix. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06149247, a Phase 2 study of Cutaneous T-Cell Lymphoma/Mycosis Fungoides, has completed, sponsored by Soligenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
Conditions Studied
Interventions
- DRUG Hypericin
- DRUG Mechlorethamine Topical Gel
Study Locations (1)
New York
- Rochester Skin Lymphoma Medical Group - Fairport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2024-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06149247
The ClinicalTrials.gov registry entry for NCT06149247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soligenix, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous T-Cell Lymphoma/Mycosis Fungoides appearing as the primary indexed condition, and to 2 interventions - of which Hypericin is the first listed.
NCT06149247 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06149247 about?
NCT06149247 is a clinical study titled "HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL". The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
What is the current status of trial NCT06149247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-12-05. Estimated completion is 2024-06-27.
What conditions does trial NCT06149247 study?
This clinical trial studies the following conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides.
What interventions are being tested in trial NCT06149247?
The interventions under investigation include: Hypericin (DRUG), Mechlorethamine Topical Gel (DRUG).
Who is sponsoring clinical trial NCT06149247?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06149247 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.